VCM
ARQT icon

Voleon Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Voleon Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Sell
57,939
-65,744
-53% -$1.53M 0.03% 396
2026
Q1 		$2.91M Sell
123,683
-52,917
-30% -$1.35M 0.06% 279
2025
Q4 		$5.13M Buy
176,600
+151,765
+611% +$3.89M 0.11% 200
2025
Q3 		$468K Buy
+24,835
New +$392K 0.01% 602

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Voleon Capital Management's ARQT Position: Q2 2026 in Review

Voleon Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 53% in Q2 2026, selling an estimated $1.53M and leaving 57,939 shares worth $1.52M. The position accounts for 0.03% of the portfolio, ranked #396.

Voleon Capital Management first reported a position in ARQT in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.13M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Voleon Capital Management held 57,939 shares of Arcutis Biotherapeutics worth $1.52M as of Q2 2026.
  • Voleon Capital Management sold 65,744 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.53M.
  • Arcutis Biotherapeutics made up 0.03% of Voleon Capital Management's portfolio in Q2 2026, its #396 holding.
  • Voleon Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's Arcutis Biotherapeutics position peaked at $5.13M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.